Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: Has the impact of anemia been overstated?

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 1, 2015, Pages 196-205

  Bishop, Andrew J ^a   Allen, Pamela K ^a   Klopp, Ann H ^a   Meyer, Larissa A ^a   Eifel, Patricia J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; DISEASES; HEMOGLOBIN; MULTIVARIANT ANALYSIS; PATIENT TREATMENT;

DISEASE-SPECIFIC SURVIVALS; DISTANT METASTASIS; HEMOGLOBIN CONCENTRATION; HEMOGLOBIN LEVELS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; STANDARD OF CARES; UNIVARIATE ANALYSIS;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; CISPLATIN; HEMOGLOBIN; HEMOGLOBIN A;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BRACHYTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FREEDOM FROM CENTRAL RECURRENCE; HAZARD RATIO; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; UTERINE CERVIX CANCER; BLOOD; COMPLICATION; EPIDEMIOLOGY; MORTALITY; REFERENCE VALUE; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHEMORADIOTHERAPY; CISPLATIN; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HEMOGLOBIN A; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REFERENCE VALUES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84923029668     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.09.023     Document Type: Article

References (21)

1. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007;25:4066-4074.
2. Harada H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res 2011;52:545-556.
3. De Los Santos JF, Thomas GM. Anemia correction in malignancy management: threat or opportunity? Gynecol Oncol 2007;105:517-529.
4. Fyles AW, Milosevic M, Pintilie M, et al. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol 2000;57:13-19.
5. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
6. Lavey RS, Liu PY, Greer BE, et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: A Southwest Oncology Group study. Gynecol Oncol 2004;95:145-151.
7. Blohmer JU, Paepke S, Sehouli J, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGOAGO intergroup study. J Clin Oncol 2011;29:3791-3797.
8. Chan P, Milosevic M, Fyles A, et al. A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 2004;70:295-299.
9. Eifel PJ, Morris M, Wharton JT, et al. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1996;29:9-16.
10. Kapp KS, Stuecklschweiger GF, Kapp DS, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1998;42:531-540.
11. Eifel PJ, Jhingran A, Brown J, et al. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer 2006;16:1106-1111.
12. Girinski T, Pejovic-Lenfant M, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16: 37-42.
13. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
14. Perez CA, Grigsby PW, Nene SM, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 1992;69:2796-2806.
15. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56: 778-787.
16. Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978;3: 302-306.
17. Lim MC, Kim JY, Kim TH, et al. Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer. Yonsei Med J 2008;49:993-1003.
18. Santin AD, Bellone S, Parrish RS, et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003;56:28-34.
19. Eisenkop S, Spirtos N, Montag T, et al. The clinical significance of blood transfusion at the time of radical hysterectomy. Obstet Gynecol 1990;76:110-113.
20. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. Blood Rev 2007;21:327-348.
21. Torti SV, Torti FM. Iron and cancer: More ore to be mined. Nat Rev Cancer 2013;13:342-355.